Last week, CSI Singapore hosted Dr. Anwesha Dey from Genentech. She spoke on the topic “Targeting the PI3K Pathway in Cancers”.

#PI3Kpathway #targetedtherapy #precisionmedicine #molecularoncology #cancerresearch #oncologyresearch #biomedicalresearch

BUT, differently from imlune alone, imlune+abema was also superior to imlune in ALL pts, including those without ESR1mut, and after previous I-line CDK4/6inhibitors (mostly palbo/ribo) and in PI3Kpathway-altered BC, with a mPFS that is superior to every ET-based regimen so far